NPM1 and acute myeloid leukemia: In this latter instance, “neoantigen-specific DLI” to elicit graft-versus-leukemia could be an attractive option for NPM1-mutated AML patients, experiencing either morphologic or molecular relapse after allogeneic HSCT [15, 41–45].